Proactiveinvestors USA & Canada Humanigen Inc https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Humanigen Inc RSS feed en Thu, 19 Sep 2019 20:12:32 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Humanigen inks licensing agreement with the University of Zurich to strengthen its treatment of graft-versus-host disease in leukemia patients ]]> https://www.proactiveinvestors.com/companies/news/314161/humanigen-inks-licensing-agreement-with-the-university-of-zurich-to-strengthen-its-treatment-of-graft-versus-host-disease-in-leukemia-patients-14161.html Mon, 22 Jul 2019 14:18:00 -0400 https://www.proactiveinvestors.com/companies/news/314161/humanigen-inks-licensing-agreement-with-the-university-of-zurich-to-strengthen-its-treatment-of-graft-versus-host-disease-in-leukemia-patients-14161.html <![CDATA[News - NA Proactive News snapshot: Klondike Gold, Chemistree Tech, Ximen Mining - UPDATED ]]> https://www.proactiveinvestors.com/companies/news/224297/na-proactive-news-snapshot-klondike-gold-chemistree-tech-ximen-mining---updated-224297.html Mon, 22 Jul 2019 11:30:00 -0400 https://www.proactiveinvestors.com/companies/news/224297/na-proactive-news-snapshot-klondike-gold-chemistree-tech-ximen-mining---updated-224297.html <![CDATA[News - Humanigen bolsters treatment of graft-versus-host disease in leukemia patients via licensing agreement with the University of Zurich ]]> https://www.proactiveinvestors.com/companies/news/224286/humanigen-bolsters-treatment-of-graft-versus-host-disease-in-leukemia-patients-via-licensing-agreement-with-the-university-of-zurich-224286.html Mon, 22 Jul 2019 09:15:00 -0400 https://www.proactiveinvestors.com/companies/news/224286/humanigen-bolsters-treatment-of-graft-versus-host-disease-in-leukemia-patients-via-licensing-agreement-with-the-university-of-zurich-224286.html <![CDATA[News - Humanigen teams up with Kite to treat a type of lymphoma cancer ]]> https://www.proactiveinvestors.com/companies/news/313685/humanigen-teams-up-with-kite-to-treat-a-type-of-lymphoma-cancer-13685.html Mon, 10 Jun 2019 14:13:00 -0400 https://www.proactiveinvestors.com/companies/news/313685/humanigen-teams-up-with-kite-to-treat-a-type-of-lymphoma-cancer-13685.html <![CDATA[News - Humanigen and Gilead's Kite to work on study to evaluate Yescarta with lenzilumab to treat a type of lymphoma ]]> https://www.proactiveinvestors.com/companies/news/221315/humanigen-and-gilead-s-kite-to-work-on-study-to-evaluate-yescarta-with-lenzilumab-to-treat-a-type-of-lymphoma-221315.html Fri, 31 May 2019 09:35:00 -0400 https://www.proactiveinvestors.com/companies/news/221315/humanigen-and-gilead-s-kite-to-work-on-study-to-evaluate-yescarta-with-lenzilumab-to-treat-a-type-of-lymphoma-221315.html <![CDATA[News - Humanigen's therapy to reduce cancer-treatment side effects highlighted in premier hematology journal ]]> https://www.proactiveinvestors.com/companies/news/220527/humanigen-s-therapy-to-reduce-cancer-treatment-side-effects-highlighted-in-premier-hematology-journal-220527.html Fri, 17 May 2019 09:28:00 -0400 https://www.proactiveinvestors.com/companies/news/220527/humanigen-s-therapy-to-reduce-cancer-treatment-side-effects-highlighted-in-premier-hematology-journal-220527.html <![CDATA[News - Humanigen unveils promising results from Ifabotuzumab Phase I study at the American Association for Cancer Research's annual meeting ]]> https://www.proactiveinvestors.com/companies/news/217658/humanigen-unveils-promising-results-from-ifabotuzumab-phase-i-study-at-the-american-association-for-cancer-research-s-annual-meeting-217658.html Mon, 01 Apr 2019 09:14:00 -0400 https://www.proactiveinvestors.com/companies/news/217658/humanigen-unveils-promising-results-from-ifabotuzumab-phase-i-study-at-the-american-association-for-cancer-research-s-annual-meeting-217658.html <![CDATA[News - Humanigen's new data show increase in mice survival with lenzilumab ]]> https://www.proactiveinvestors.com/companies/news/312772/humanigen-s-new-data-show-increase-in-mice-survival-with-lenzilumab-12772.html Thu, 28 Mar 2019 12:56:00 -0400 https://www.proactiveinvestors.com/companies/news/312772/humanigen-s-new-data-show-increase-in-mice-survival-with-lenzilumab-12772.html <![CDATA[News - Humanigen presents new study showing lenzilumab's potential to fight tumors ]]> https://www.proactiveinvestors.com/companies/news/217031/humanigen-presents-new-study-showing-lenzilumab-s-potential-to-fight-tumors-217031.html Fri, 22 Mar 2019 08:15:00 -0400 https://www.proactiveinvestors.com/companies/news/217031/humanigen-presents-new-study-showing-lenzilumab-s-potential-to-fight-tumors-217031.html <![CDATA[News - Humanigen CEO optimistic on drug candidate after pulling company from the brink ]]> https://www.proactiveinvestors.com/companies/news/215649/humanigen-ceo-optimistic-on-drug-candidate-after-pulling-company-from-the-brink-215649.html Tue, 05 Mar 2019 14:15:00 -0500 https://www.proactiveinvestors.com/companies/news/215649/humanigen-ceo-optimistic-on-drug-candidate-after-pulling-company-from-the-brink-215649.html <![CDATA[News - Humanigen pins hopes on monoclonal antibody treatment of cancer therapy's side effects ]]> https://www.proactiveinvestors.com/companies/news/215256/humanigen-pins-hopes-on-monoclonal-antibody-treatment-of-cancer-therapy-s-side-effects-215256.html Mon, 25 Feb 2019 15:28:00 -0500 https://www.proactiveinvestors.com/companies/news/215256/humanigen-pins-hopes-on-monoclonal-antibody-treatment-of-cancer-therapy-s-side-effects-215256.html <![CDATA[News - Humanigen study of monoclonal antibody in CAR-T therapy presented at Houston conference ]]> https://www.proactiveinvestors.com/companies/news/215241/humanigen-study-of-monoclonal-antibody-in-car-t-therapy-presented-at-houston-conference-215241.html Mon, 25 Feb 2019 09:19:00 -0500 https://www.proactiveinvestors.com/companies/news/215241/humanigen-study-of-monoclonal-antibody-in-car-t-therapy-presented-at-houston-conference-215241.html <![CDATA[News - Humanigen study of its monoclonal antibody in CAR-T therapy featured in medical journal ]]> https://www.proactiveinvestors.com/companies/news/214733/humanigen-study-of-its-monoclonal-antibody-in-car-t-therapy-featured-in-medical-journal-214733.html Fri, 15 Feb 2019 08:58:00 -0500 https://www.proactiveinvestors.com/companies/news/214733/humanigen-study-of-its-monoclonal-antibody-in-car-t-therapy-featured-in-medical-journal-214733.html <![CDATA[News - Humanigen has gleaned 'significant' interest from potential partners from its data presentation ]]> https://www.proactiveinvestors.com/companies/news/312185/humanigen-has-gleaned--significant--interest-from-potential-partners-from-its-data-presentation-12185.html Mon, 11 Feb 2019 07:52:00 -0500 https://www.proactiveinvestors.com/companies/news/312185/humanigen-has-gleaned--significant--interest-from-potential-partners-from-its-data-presentation-12185.html <![CDATA[News - Humanigen new research shows encouraging results for cancer treatment using Car-T ]]> https://www.proactiveinvestors.com/companies/news/311475/humanigen-new-research-shows-encouraging-results-for-cancer-treatment-using-car-t-11475.html Wed, 05 Dec 2018 15:53:00 -0500 https://www.proactiveinvestors.com/companies/news/311475/humanigen-new-research-shows-encouraging-results-for-cancer-treatment-using-car-t-11475.html <![CDATA[News - Humanigen CEO says company is developing drug to make 'the new frontier' in cancer therapy safer ]]> https://www.proactiveinvestors.com/companies/news/309440/humanigen-ceo-says-company-is-developing-drug-to-make-the-new-frontier-in-cancer-therapy-safer-9440.html Sat, 09 Jun 2018 01:32:00 -0400 https://www.proactiveinvestors.com/companies/news/309440/humanigen-ceo-says-company-is-developing-drug-to-make-the-new-frontier-in-cancer-therapy-safer-9440.html